Marketdash
Back to News

Pre-Market Movers: Snowflake Slides Despite Earnings Beat While Symbotic Tumbles on Share Offering

MarketDash Editorial Team
4 days ago
U.S. stock futures showed mixed signals Thursday morning as several big names took hits in pre-market trading. Snowflake dropped sharply despite beating revenue and earnings expectations, while Symbotic fell on news of a 10 million share offering.

Thursday morning brought mixed signals for U.S. stock futures, with the Dow futures edging up around 0.1% while several notable names struggled in pre-market action.

Snowflake's Puzzling Decline

The morning's head-scratcher comes from Snowflake Inc. (SNOW), which is getting hammered despite posting a solid earnings beat. The AI data cloud company delivered third-quarter revenue of $1.21 billion, topping analyst estimates of $1.18 billion. Adjusted earnings came in at 35 cents per share, beating expectations of 31 cents per share.

So why the sell-off? Sometimes beating estimates isn't enough if guidance disappoints or growth rates decelerate, though the market's reaction suggests investors found something less than thrilling in the details. Snowflake shares tumbled 8.6% to $241.85 in pre-market trading.

Other Notable Decliners

Net Lease Office Properties (NLOP) led the decliners, plunging 14.7% to $25.19 in pre-market action. That's a rough morning for the office property REIT.

Symbotic Inc. (SYM) dropped 10.5% to $65.50 after announcing a 10 million share offering. The warehouse automation company plans to sell 6.5 million new shares while a selling stockholder will offload another 3.5 million. Dilution fears are hitting the stock hard.

Capricor Therapeutics Inc. (CAPR) gave back some of Wednesday's massive gains, falling 8.4% to $27.45. This comes after the biotech rocketed 371% higher Wednesday on news that its Phase 3 HOPE-3 trial evaluating deramiocel cell therapy for Duchenne Muscular Dystrophy met its primary endpoint and secondary cardiac endpoint. A pullback after a move like that isn't exactly shocking.

ADC Therapeutics SA (ADCT) declined 8.1% to $3.63, extending Wednesday's 14% drop. The company recently reported updated data from its LOTIS-7 trial evaluating Zynlonta in combination with Glofitamab in relapsed/refractory DLBCL patients, and the market's reaction suggests the data didn't impress.

Rounding out the decliners: Lineage Cell Therapeutics Inc. (LCTX) fell 7.1% to $1.56, Koninklijke Philips NV (PHG) dropped 6.8% to $26.11, Omeros Corp. (OMER) declined 4.2% to $10.18, and Methanex Corp. (MEOH) slipped 3.8% to $35.95 in pre-market trading.

Back to News

Pre-Market Movers: Snowflake Slides Despite Earnings Beat While Symbotic Tumbles on Share Offering

MarketDash Editorial Team
4 days ago
U.S. stock futures showed mixed signals Thursday morning as several big names took hits in pre-market trading. Snowflake dropped sharply despite beating revenue and earnings expectations, while Symbotic fell on news of a 10 million share offering.

Thursday morning brought mixed signals for U.S. stock futures, with the Dow futures edging up around 0.1% while several notable names struggled in pre-market action.

Snowflake's Puzzling Decline

The morning's head-scratcher comes from Snowflake Inc. (SNOW), which is getting hammered despite posting a solid earnings beat. The AI data cloud company delivered third-quarter revenue of $1.21 billion, topping analyst estimates of $1.18 billion. Adjusted earnings came in at 35 cents per share, beating expectations of 31 cents per share.

So why the sell-off? Sometimes beating estimates isn't enough if guidance disappoints or growth rates decelerate, though the market's reaction suggests investors found something less than thrilling in the details. Snowflake shares tumbled 8.6% to $241.85 in pre-market trading.

Other Notable Decliners

Net Lease Office Properties (NLOP) led the decliners, plunging 14.7% to $25.19 in pre-market action. That's a rough morning for the office property REIT.

Symbotic Inc. (SYM) dropped 10.5% to $65.50 after announcing a 10 million share offering. The warehouse automation company plans to sell 6.5 million new shares while a selling stockholder will offload another 3.5 million. Dilution fears are hitting the stock hard.

Capricor Therapeutics Inc. (CAPR) gave back some of Wednesday's massive gains, falling 8.4% to $27.45. This comes after the biotech rocketed 371% higher Wednesday on news that its Phase 3 HOPE-3 trial evaluating deramiocel cell therapy for Duchenne Muscular Dystrophy met its primary endpoint and secondary cardiac endpoint. A pullback after a move like that isn't exactly shocking.

ADC Therapeutics SA (ADCT) declined 8.1% to $3.63, extending Wednesday's 14% drop. The company recently reported updated data from its LOTIS-7 trial evaluating Zynlonta in combination with Glofitamab in relapsed/refractory DLBCL patients, and the market's reaction suggests the data didn't impress.

Rounding out the decliners: Lineage Cell Therapeutics Inc. (LCTX) fell 7.1% to $1.56, Koninklijke Philips NV (PHG) dropped 6.8% to $26.11, Omeros Corp. (OMER) declined 4.2% to $10.18, and Methanex Corp. (MEOH) slipped 3.8% to $35.95 in pre-market trading.